NEW YORK (GenomeWeb News) – Invitrogen said yesterday that has signed a co-exclusive agreement with Qualyst to offer hepatocyte screening services and research products.
Invitrogen said that its wholly-owned subsidiary, CellzDirect, will provide in-house services and commercialized kits that combine Qualyst’s B-Clear technology with CellzDirect’s cell products, which include hepatocytes and products focused on drug metabolism and transport. Qualyst’s B-clear technology enables in vivo and in vitro prediction of hepatobiliary disposition, hepatic uptake, hepatic efflux, biliary clearance, and drug transport, the firms said.
The combination of the technologies “will create robust hepatocyte testing systems to help pharmaceutical companies avoid costly drug development challenges and expedite the development of safe and effective drugs,” Rob Brainin, vice president and general manager of CellzDirect, said in a statement.
The firms expect the new services to be available through Invitrogen in mid-December. Financial terms of the collaboration were not disclosed.
Invitrogen acquired CellzDirect for $57 million in cash in January.